Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02633293 · ClinicalTrials.gov registry record · Phase 2
An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
A Phase 2 study, sponsored by United Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 243
- Enrollment target
NCT02633293 is a Phase 2 study that was terminated before completion, run by United Therapeutics. The registered enrollment target is 243 participants.
The verdict
NCT02633293, a Phase 2 study, was terminated before completion, sponsored by United Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 243 participants
- Enrollment target
Study Summary
This is a multicenter, open-label trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study will include about 266 patients who completed all required assessments in the RIN-PH-201 study at approximately 100 clinical trial centers. The study will continue Your participation in this study is voluntary and will last until you discontinue from the study or the study ends. The study will continue until each subject reaches the Week 108 visit or until inhaled treprostinil become commercially available for patients with PH associated with ILD including CPFE (whichever is sooner).
Interventions
- DRUG Inhaled Treprostinil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2016-09-15 |
| Est. Completion | 2021-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02633293
The ClinicalTrials.gov registry entry for NCT02633293 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 243 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Inhaled Treprostinil is the first listed.
NCT02633293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02633293 about?
NCT02633293 is a clinical study titled "An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE". This is a multicenter, open-label trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study will include about 266 ...
What is the current status of trial NCT02633293?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 243 participants. The study started on 2016-09-15. Estimated completion is 2021-08-01.
What interventions are being tested in trial NCT02633293?
The interventions under investigation include: Inhaled Treprostinil (DRUG).
Who is sponsoring clinical trial NCT02633293?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.